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Multidrug resistance (MDR) is the major confounding factor in adjuvant solid tumour chemotherapy. Increasing intracellular amounts
of chemotherapeutics to circumvent MDR may be achieved by a novel delivery method, photochemical internalisation (PCI). PCI
consists of the co-administration of drug and photosensitiser; upon light activation the latter induces intracellular release of organelle-
bound drug. We investigated whether co-administration of hypericin (photosensitiser) with mitoxantrone (MTZ, chemotherapeutic)
plus illumination potentiates cytotoxicity in MDR cancer cells. We mapped the extent of intracellular co-localisation of drug/
photosensitiser. We determined whether PCI altered drug-excreting efflux pump P-glycoprotein (Pgp) expression or function in
MDR cells. Bladder and breast cancer cells and their Pgp-overexpressing MDR subclones (MGHU1, MGHU1/R, MCF-7, MCF-7/R)
were given hypericin/MTZ combinations, with/without blue-light illumination. Pilot experiments determined appropriate sublethal
doses for each. Viability was determined by the 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide assay. Intracellular
localisation was mapped by confocal microscopy. Pgp expression was detected by immunofluorescence and Pgp function investigated
by Rhodamine123 efflux on confocal microscopy. MTZ alone (0.1–0.2mgml
 1) killed up to 89% of drug-sensitive cells; MDR cells
exhibited less cytotoxicity (6–28%). Hypericin (0.1–0.2mM) effects were similar for all cells; light illumination caused none or minimal
toxicity. In combination, MTZ /hypericin plus illumination, potentiated MDR cell killing, vs hypericin or MTZ alone. (MGHU1/R: 38.65
and 36.63% increase, Po0.05; MCF-7/R: 80.2 and 46.1% increase, Po0.001). Illumination of combined MTZ/hypericin increased
killing by 28.15% (Po0.05 MGHU1/R) compared to dark controls. Intracytoplasmic vesicular co-localisation of MTZ/hypericin was
evident before illumination and at serial times post-illumination. MTZ was always found in sensitive cell nuclei, but not in dark resistant
cell nuclei. In illuminated resistant cells there was some mobilisation of MTZ into the nucleus. Pgp expression remained unchanged,
regardless of drug exposure. Pgp efflux was blocked by the Pgp inhibitor verapamil (positive control) but not impeded by hypericin.
The increased killing of MDR cancer cells demonstrated is consistent with PCI. PCI is a promising technique for enhancing treatment
efficacy.
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Resistance to multiple antineoplastic chemotherapeutic agents
restricts the efficacy of cancer therapy (Leslie et al, 2005). Cancer
progression is commonly associated with the formation of
subcolonies within the heterogeneous tumour. Dependent on
selection pressures, only a phenotypically elite subpopulation will
survive. Exposure to chemotherapeutic drugs is an example of
such a selection pressure from which only some of the tumour cells
will survive by expressing a multidrug-resistant (MDR) phenotype,
which renders them refractive to treatment. Two underlying
mechanisms are (1) the overexpression of P-glycoprotein (Pgp)
efflux pumps that eject drugs from the cytosol and (2) the action of
lysosomes in degrading drugs taken up by endosomes.
A well-studied mechanism for MDR is the decrease in cellular
drug accumulation mediated by the ATP-binding cassette (ABC)
family of transporters. ABC transporters, for example, Pgp
membrane efflux pumps, are expressed in normal tissues including
intestinal epithelia, liver, renal tubules, and lung, where they
mediate the efflux of toxins and drugs (Han and Zhang, 2004; Leslie
et al, 2005). Transporter overexpression by a colony of tumour
cells causes the expulsion from the cytoplasm of anti-cancer
drugs before they reach their site of action and results in cellular
and clinical MDR. Although initially attributed only to Pgp
upregulation (Ambudkar et al, 1999), MDR may result from
various overexpressed ABC transporters, eg, cancer-resistance
protein and MDR-associated proteins (Shepard et al, 2003; Lepper
et al,2 0 0 5 ) .
A number of macromolecular and low molecular weight drugs
do not bind cell surface receptors but are targeted to intracellular
compartments. Often unable to freely diffuse across lipid
membranes, drugs are taken up by endocytosis before they can
be released intracellularly to reach their targets. Endocytosed
drugs may be degraded in lysosomes and this stops their biological
activity. One MDR mechanism in cancer is the upregulation of this
process to significantly limit drug efficacy (Høgset et al, 2004).
Photochemical internalisation (PCI) is an extension of photo-
dynamic therapy. The principle of PCI is to localise the
photosensitiser together with the drug or gene of choice in
endocytic vesicles within target cells, with the photosensitiser
specifically localising to the vesicular membrane (Høgset et al,
2004; Ndoye et al, 2004; Dietze et al, 2005). Irradiation of cells with
light of a specific wavelength will excite the photosensitiser to
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sproduce reactive oxygen species which subsequently rapture the
membranes (Figure 1), resulting in drugs release. (Høgset et al,
2004; Ndoye et al, 2004; Dietze et al, 2005). Consequently, PCI
enables a more efficient delivery of drug to their intracellular
targets (Berg et al, 1999; Selbo et al, 2001; Høgset et al, 2004). In
cancer treatment, PCI as a more selective procedure than systemic
chemotherapy will have reduced systemic effects and its activity
can be restricted to irradiated tissues.
PCI has been shown to potentiate the biological activity of
various macromolecules (Berg et al, 2003), eg, the type I ribosome-
inactivating protein Gelonin (Barbieri et al, 1993). This single-
chain polypeptide cannot bind to the cell surface nor facilitate its
own release from endocytic vesicles (Stirpe et al, 1980). Although a
powerful inhibitor of protein synthesis in cell-free systems, it has
low toxicity in intact cells and or in vivo (Barbieri and Stirpe, 1982;
Scott et al, 1987). Gelonin localised in the same intracellular
compartments as the photosensitiser disulphonated aluminium
phthalocyanine (Selbo et al, 2000); the latter has been shown to
localise within endocytic vesicles both in vitro (Moan et al, 1989)
and in vivo (Høgset et al, 2004). Illumination of cells containing
the two agents resulted in drug release into the cytoplasm (Høgset
et al, 2004). PCI of gelonin resulted in a 300-fold reduction of
protein synthesis compared to exposure to gelonin alone or light
plus photosensitiser (PDT) alone.
Glucosylated polyethylenimine (PEI) in conjunction with PCI
enhanced nonviral-mediated transfer of wt-p53 into p53-deleted
PANC3 (pancreas carcinoma) and p53-mutated FaDu (pharynx
carcinoma) lines. PCI resulted in increased p53 mRNA expression
by 2.3-fold in PANC3 cells, compared to PEI alone (Ndoye et al,
2004). PCI also increased apoptosis in both lines to levels similar to
those achieved with chemotherapy. Thus by facilitating the release
of wild-type p53 from endocytic vesicles, PCI enhanced both the
expression of p53 and its activity (spontaneous apoptosis)
compared to PEI alone in human cancer cell lines. The findings
support PCI as an alternative procedure for gene delivery into the
cytosol of target cells (Berg et al, 1999).
In a previous study involving our department, the photosensi-
tiser disulphonated meso-tetraphenylporphyrin (TPPS2a) was
co-administered with the anticancer drug doxorubicin, to a
drug-sensitive breast cancer cell line and its resistant counterpart
(MCF-7/S, MCF-7/R). Doses used for both agents were those that
resulted in 50% cellular cytotoxicity. Strikingly, the administration
and irradiation of TPPS2a, followed by doxorubicin incubation,
resulted in significant increased killing for the MDR cells.
Following confocal microscopy tracking, the authors suggested
that this was due to the fact that endolysosomal vesicles which had
incorporated TPPS2a were destroyed upon illumination and
therefore did not trap the drug doxorubicin (Lou et al, 2006).
We therefore decided to explore the use of PCI in circumventing
drug resistance in two pairs of human cancer cell lines, comprising
both drug-sensitive parental lines and MDR subclones, specifically
the bladder and breast cancer cell lines MGHU1/S and MGHU1/R,
and MCF-7/S and MCF-7/R. We also decided to investigate
cytotoxic effects of sublethal concentrations of drugs, using the
chemotherapeutic mitoxantrone (MTZ) and as photosensitiser the
St John’s Wort extract hypericin. The anthraquinone, hypericin, is
synthesised by the hypericum genus of plants and it is probably the
most powerful photosensitiser found in nature. Hypericin exhibits
the characteristics that are fundamental for the application of PDT,
including bright fluorescence, a high singlet oxygen quantum yield
upon illumination and minimal dark toxicity (Agostinis et al,
2002). Previous PDT studies on the effect of hypericin on cultured
fibroblasts or murine keratinocytes have shown concentration-
and light-dependent phototoxicity (Yu et al, 1996; Theodossiou
et al, 2004). Recently, an additional hypericin phototoxic mecha-
nism against mitochondria has been identified. This does not
depend on glutathione/H2O2 homeostasis (Theodossiou et al,
2006). Hypericin has also been shown to induce PDT in cancer
cells in vitro (Assefa et al, 1999). However, no studies to date have
investigated hypericin within the context of PCI.
We first determined the relative effect of hypericin-PDT and
secondly we examined whether PCI using low dose hypericin was
able to potentiate the cytotoxicity of MTZ on these cell lines.
MATERIALS AND METHODS
Cell culture preparation
Two sets of human cancer cell lines were used: (1) bladder cancer
MGHU1/S (Masters et al, 1986) and its MDR counterpart MGHU1/
R (grown in increasing adriamycin (ADR) concentrations, Govern
et al, 1988); (2) breast cancer MCF-7/S (European Collection of
Animal Cell Cultures, Porton Down, UK) and its MDR counterpart
MCF-7/R. All, but MCF-7, were donated by Professor Masters,
Prostate Cancer Research Centre, UCL. We previously showed Pgp
overexpression by MGHU1/R and MCF-7/R (Davies et al, 1999).
Cells were routinely grown in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% (v/v) fetal calf serum (FCS) and 0.1% (v/v)
gentamycin, at 371C. Cells were trypsinised (1mgml
 1 in 0.2%
phosphate-buffered saline (PBS)/EDTA), centrifuged ( 2, 400g,
5min) and used for passage or further experimental work. For
plating into 96-well plates (100mlwell
 1), cells were re-suspended
at 100000 cells/100ml (MGHU1/S&R) or 200000 cells/100ml (MCF-
7/S&R). The different plating numbers reflected growth rates and
ensured equivalent growth. (Reagents from Sigma, Dorset, UK,
unless stated otherwise).
Mitoxantrone and hypericin dose–response curves
Mitoxantone Concentrations to be used in later combination
experiments were determined by exposing cells to MTZ concen-
trations from 0.1 to 2mgml
 1. Cells were seeded in 96 well plates
PS
PS
PS
PS
PS
PS
PS
PS
PS
1.
2.
3.
Figure 1 Diagrammatic representation of PCI. (1) Photosensitiser (PS)
and cytotoxic drug ( ) incorporate into the inner layer of the phospholipid
membrane of the target cell. (2) Endocytosed PS preferentially localises
to the endocytic vesicular membrane with cytotoxic drug situated in
the lumen. Upon irradiation with light of a specific wavelength the
photosensitiser is excited, which in the presence of molecular oxygen
produces reactive oxygen species, singlet oxygen being of particular
importance. (3) These degrade and rupture the membrane releasing the
cytotoxic drug directly into the cytosol.
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s(see Cell culture preparation) for 24h, incubated with MTZ for a
further 24h at 371C, in a humidified 5% CO2 atmosphere and
allowed to recover for 24h. Wells were washed twice (PBS) after
drug exposure and waste was removed using a suction pump at
each stage. Viability was assayed by the MTT assay.
Hypericin Experimental conditions for hypericin concentrations
and illumination time for further combination experiments were
determined as follows.
Time of hypericin exposure Cells were exposed to hypericin for
4h, which is sufficient time for the agent to be internalised
(Theodossiou et al, 2004).
Dose response Cells were plated as described in Figure 2, wrapped
in aluminium foil and allowed to settle and grow for 24h at 371C,
5% CO2. At this time, media in the wells was replaced with fresh
media for a further 20h and then media was again replaced with
hypericin at 0.1, 0.2, 0.4, or 1.0mM for 4h at 371C, 5% CO2. Cells
were washed and plates were illuminated for 1, 2, or 5min. The
cells were allowed to recover for a further 24h, washed in PBS and
assayed by MTT (Figure 2). All experimental steps, apart from
illumination, were carried out in the dark to avoid inappropriate
hypericin photoactivation; plates were wrapped in aluminium foil
while in the incubator and lights were off in the laminar flow
cabinets during cell work. The ‘dark’ control plates were never
illuminated or exposed to light.
Combination experiments
Combination experiments were carried out under dark conditions
(see Mitoxantrone and hypericin dose-response curves). Cells
were plated in 96-well plates for 24h, 371C, 5% CO2, at which point
media was removed and replaced with one of the following: (1)
MTZ alone for 24h; (2) MTZ for 20h, followed by washing
(2 PBS) and incubation with MTZ/hypericin containing media
for 4h; (3) fresh media for 20h followed by hypericin containing
media for 4h; and (4) media alone in control wells. All non-
combination wells were washed at 20h and media containing
appropriate agents replaced, to control for media change and fresh
agents in the combination group (Figure 2). At the end of the 24h
incubation, cells were thoroughly washed and fresh media was
replaced in the wells. Plates were illuminated for 2min with blue
light, Lumisource (maximum output at 420nm 7mWcm
 2; PCI
Biotech, Oslo, Norway) (120s 7mWcm
 2 equivalent to
840mJcm
 2), and subsequently incubated for a further 24h,
371C, 5% CO2. Viability was assessed using MTT. Drug concentra-
tions used were 0.1 and 0.2mgml
 1 MTZ, 0.1mM and 0.2mM
hypericin, alone, or in combinations. Control ‘dark’ plates were
neither exposed to light nor illuminated. Control ‘normal light’
plates were not covered in aluminium foil or prepared in the dark
or illuminated.
MTT assay
The 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide
(MTT) assay was used to determine cellular viability. Cell survival
is quantified by assessing mitochondrial activity, that is, the
reduction by mitochondrial dehydrogenases of the hydrophilic
tetrazonium salt to a purple, insoluble formazan derivative. The
latter’s density is quantified by its absorption of visible light
(570nm). MTT (1mgml
 1) was added to each well (100ml) and
cells incubated for 3h, 371C, 5% CO2 (Uehlinger et al, 2000). MTT
was replaced with dimethyl sulphoxide (100ml/well) to dissolve
formazan crystals. Absorption was read on the plate reader (MR
700 Dynatech; 570nm bandpass filter).
Hypericin cellular uptake
The four cell lines were plated as described. After incubation (24h,
371C, 5% CO2), the medium was replaced and cells were incubated
for another 20h. At this time the medium was replaced with 1mM
hypericin (100ml/well) and re-incubated for 4h. Hypericin was
washed off, replaced with PBS and intracellular hypericin
fluorescence measured using a fluorescence reader (LS50B
Perkin-Elmer fluorescence spectrometer, Beaconsfield, UK).
Protocol for imaging experiments using MTZ and
hypericin
Pgp expression (see Immunofluorescence staining for Pgp expres-
sion) and the intracellular localisation of MTZ and hypericin were
investigated by growing cells on glass for microscopic visualisa-
tion. Cells were grown on 13mm glass coverslips in 24-well plates
(100000/100ml for MCF-7, MCF-7/R and 50000/100ml for
MGHU1/S, MGHU1/R; 371C, 5% CO2). After settling for 24h, cells
were designated to receive MTZ, hypericin, or a combination of the
two. The incubation times followed are described in 2.5. The
concentrations used were 1 or 2mgml
 1 MTZ and 1 or 2mM
hypericin either singly or in combination. After drug incubation
(24h), cells were washed and illuminated for 2–4min to ensure full
photoactivation and then replaced in the incubator for 1, 4, 16, 20,
or 24h. Experiments were carried out under dark conditions, apart
from the illumination. Cells were viewed live to map intracellular
drug localisation by detecting their natural fluorescence or they
were fixed for Pgp immunofluorescence.
Confocal microscopy for MTZ and hypericin localisation
Digital imaging of live cells to detect localisation of naturally
fluorescent MTZ and hypericin was performed using a Zeiss
confocal microscope (Carl Zeiss Ltd, Welyn Garden City, UK)
equipped with a  63 water immersion objective lens.
The strongly fluorescent hypericin often gives rise to ‘crosstalk’
when imaging in the presence of other fluorescent dyes, eg,
organelle probes such as lysotracker, resulting in misleading
observations (Theodossiou et al, 2004; Taroni et al, 2005).
Therefore, we carried out fluorescence emission and excitation
scans to determine the most ideal excitation and emission spectra
for each drug with minimum or no overlap of emission in the two
drugs’ spectra upon detection. Three lasers were tested (488, 568,
and 633nm) to excite the specimens in all concurrent combina-
tions and orders. Specifically, when hypericin-treated cells were
excited with the 488nm laser the main emission peak was at
595nm with a secondary peak at 650nm, but still detectable at
690nm (where MTZ may be detected). Figure 3 highlights this
‘crosstalk’ effect of hypericin. When excited with the 633nm laser,
no fluorescence was detected at 660nm and 690nm. In turn, MTZ
Illumination
Drug  MTT 
Mitoxantrone 
Hypericin 
02 4 4 4 4 8 7 2
Time (h)
Figure 2 Experimental timeline for PCI on cells. PBS saline washes were
performed after each drug incubation to ensure drug removal from cell
cultures.
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swas found to have strong signals in two channels, particularly
when excited with 633nm. Of the two channels, 660nm and
690nm, the latter detected clearly both intranuclear and intra-
cytoplasmic MTZ. We therefore decided to excite the two drugs
separately with two different lasers; Specimens were exposed to a
488nm laser to excite hypericin; emission was detected at 590nm.
Cells were then excited with the 633nm laser for MTZ and detected
at 690nm. Images were overlaid for final combination images.
Additionally, lysotracker green DnD-26 (50nM; Invitrogen Ltd,
Paisley, UK) was added to some hypericin treated coverslips half
an hour before illumination and was incubated at 371C, to
investigate co-localisation within lysosomes. For detection, cells
were excited with a 488nm laser (both agents); lysotracker
emission was detected at 510nm while hypericin was detected at
590nm, with no crosstalk. The experiment was carried out with/
without illumination, and lysotracker only controls.
Immunofluorescence staining for Pgp expression
P-glycoprotein expression was detected by indirect immunofluor-
escence, using a mouse anti-human monoclonal anti-Pgp antibody
(IgG1) and a goat anti-mouse IgG1 secondary antibody (fluorescein-
conjugated) (Oxford Biotechnology Ltd, Kidlington, Oxon, UK),
detected by fluorescent microscopy (Carl Zeiss Ltd, Welyn
Garden City, UK).
Cells were grown on 13mm coverslips and treated with MTZ
and/or hypericin as described (2.6). Coverslips were washed in
PBS, fixed in acetone:methanol (50:50) (room temperature,
6min), washed (3 PBS) and stored (PBS, 41C). For immuno-
florescence, coverslips were incubated with the primary antibody
(1:20 in PBS, 1h, room temperature), washed in PBS (3 ),
incubated with the secondary antibody (1:50 in PBS, 1h, 4
oC,
dark). After a final BPS wash (3 ) coverslips were mounted onto
slides using citifluor and stored at 41C in the dark, till visualisation
under the microscope.
Other fixing methods were inferior (100% acetone, paraformal-
dehyde, gluteraldehyde).
Determination of Pgp function
To investigate whether hypericin impaired Pgp function, we
compared it against verapamil, a known Pgp inhibitor. Pilot
experiments determined that, in MGHU1/R cells, 24h co-incuba-
tion of MTZ (0.1mgml
 1—which by itself kills o5% of resistant
cells) with verapamil (0.1–10mM) reversed the resistant phenotype
in a dose dependent manner (increased killing: o5% for 0.1mM
verapamil; 18% increased killing for 1mM verapamil; 40% for 5mM;
detailed results not shown). To compare the effect of hypericin on
Pgp function with that of verapamil, we used the exact incubation
conditions of hypericin and verapamil which increased killing (ie,
0.1mM HYP incubated for 4h and verapamil incubated for 24h)
and investigated changes in Pgp efflux using Rhodamine123, a
standard Pgp efflux agent. Our method is an adaptation of the
seminal method for Pgp efflux assessment using flow cytometry
described by Wang et al (2000, 2004).
Resistant cells were grown on 13mm glass as above for 48h. At
24h cells received verapamil (0.1, 1, 10mM) for another 24h or at
42h cells received hypericin (0.1mM) for another 4h (removal by
washing, plus illumination). Cells were washed and Rhodamine123
(200ngml
 1 in full medium) was ‘loaded’ onto the cells during a
30-min incubation (371C, 5% CO2, humidity). Cells were washed
immediately before confocal visualisation and left in PBS.
Rhodamine123 was excited at 488nm and fluorescent signal
collected at 500–550nm (no interference by hypericin crosstalk
was detected). Images were taken every 30s, for 20min.
Fluorescence uptake was heterogeneous in different cells with
signal always localising in the cytoplasm. Changes in signal
intensity over time was calculated for each cell by drawing
cytoplasmic regions of interest (in approximately eight cells per
coverslip) and calculating the per cent decrease in intensity for
each cell after 20min of efflux.
Statistical analysis
Single agent and combination viability experiments were repeated
6–12 times. Raw data underwent one-way ANOVA followed by
appropriate post hoc analysis, Tukeys (multiple simultaneous
comparisons), or Dunnets (dose–response curves for single agents).
When all light vs all dark data were compared (to identify
differences in the killing effect of illuminated and dark HYPþMTZ
combinations), the dark control data was consistently slightly lower
than the light control data (o10%) and the former was normalised
based on the difference of means of the two untreated control
groups. Analysis was carried out on normalised data by one-way
ANOVA followed by Bonferroni’s multiple comparisons test, which
takes into account unequal group sizes. Although data are
parametric and were analysed statistically as such, the majority
are depicted graphically or described in terms of percentages, for
clarity. Confocal experiments were repeated a minimum of eight
times. Pgp efflux confocal measurements were also parametric,
however the uptake of fluorescent Rhodamine123 was hetero-
geneous and the resultant decrease values had a fairly wide range,
unlike the experiments carried out in 96-well plates. Therefore, the
data was submitted to Mann–Whitney non-parametric analysis.
RESULTS
Mitoxantrone and hypericin dose–response curves
Mitoxantrone Cell viability was assessed after MTZ incubation
followed by a 24h recovery period. Killing rates of approximately
6 and 28% were detected for MGHU1/R and 80 and 89% were
Figure 3 Cells treated with hypericin (HYP) and excited with 488nm laser (16h post-illumination). Detection of fluorescence at (A) 590nm, (B) 660nm
and (C) 690nm. The images highlight the highly fluorescent nature of HYP and the ‘spillover’ problem it presents when attempting to isolate its detection in
one channel.
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sdetected for MGHU1/S for 0.1 and 0.2mgml
 1 MTZ, respectively.
By 2mgml
 1 of MTZ, killing was increased to 60% for resistant
cells and 95% for sensitive cells. In contrast, both MCF7 cell lines
were more resistant to low doses of MTZ than MGHU1 cell lines.
MTZ at 0.1 and 0.2mgml
 1 killed 6 and 13% of MCF-7/R and 16
and 26% of MCF-7/S. By 2mgml
 1, MTZ killed 60 and 83% of
resistant and sensitive cells respectively. MTZ doses chosen to be
used for combination experiments were 0.1 and 0.2mgml
 1; with
these doses cell viability is still evident and therefore further added
toxicity from hypericin can be detected.
Hypericin Cells were incubated with hypericin for 4h, before
illumination with blue light (1, 2, or 5min); cell viability was assessed
24h later. Generally, the longer the duration of light, the more
evident the phototoxic effect of hypericin at a lower dose: Using
MGHU1/R as an example, with 1min illumination hypericin had
evident phototoxic effects from 0.4mM. (viability reduced to 60% of
control); with 2min illumination hypericin had effects from 0.2mM
(viability reduced to 64%); and with 5min illumination hypericin
effects were evident at 0.1mM (viability reduced to 21.2%).
Generally, parental cell lines were less susceptible to hypericin
than their MDR counterparts. Figures 4A and B illustrate ‘dark’
and light activated (2min) toxicity of hypericin in MGHU1/R and
MGHU1/S cells. Unlike the pattern in the drug-sensitive cells, the
resistant cells exhibited some ‘dark’ cytotoxicity to hypericin
(0.1mM, 0.2mM). Cellular killing was on average 13% more in the
illuminated MDR cells compared to ‘dark’ controls (Po0.05),
demonstrating direct phototoxicity. An interesting observation
was made with the MCF-7 cell lines: Both MCF-7R and MCF-7/S
cells appeared to proliferate in response to hypericin plus
illumination (Po0.05 light vs dark, MCF-7/S at 0.2mM HYP;
MCF-7/R at 0.1mM HYP). At higher doses, cells succumbed to the
toxic effects of hypericin plus illumination, with MCF-7/S cells
being susceptible from 0.4mM (not shown) and MCF-7/R from
0.2mM of hypericin. Similarly to MGHU1/R, MCF-7/R exhibited
some dark cytotoxicity (Figure 4C and D). The differences
observed between the four cell lines appear to be independent of
the level of hypericin uptake as shown in the level of fluorescence
emitted at 605nm. There was no significant difference in initial
hypericin uptake, with an average of 3.6–3.9 (fluorescence
emitted) across all four cell lines.
Hypericin doses chosen to be used in the combination
experiments were 0.1 and 0.2mM. At these concentrations the killing
effect (with or without illumination) is minimal or non-existent,
thus it is possible to determine if hypericin has an additive and/or
synergistic effect when combined with MTZ. The duration of
illumination chosen for the combination experiments was 2min,
which is a compromise between minimal level of cytotoxicity in the
MGHU1 cell lines and reducing the apparent phenomenon of
cellular proliferation, at lower doses, in the MCF-7 cell lines.
Mitoxantrone and hypericin combination effects on cell
viability
Cells were incubated with MTZ for 20h, then a combination of
hypericin and MTZ (4h), before being illuminated (2min).
Viability was assessed 24h later.
MGHU1/R cells exhibited increased killing when exposed to the
hypericinþMTZ combination, compared to hypericin or MTZ
alone (Figure 5A). There was a 38.65 and 36.63% decrease in cell
viability of MGHU1/R cells when exposed to hypericin (0.1mM)þMTZ
(0.1mgml
 1) combination, compared to hypericin (PDT) or MTZ
alone (Po0.05), respectively (Figure 5A). There was also a significant
decrease in cell viability (by 34%) of MGHU1/R cells when exposed to
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Figure 4 Bladder cancer cells (A) MGHU1/S and (B) MGHU1/R and breast cancer cells (C) MCF-7/S and (D) MCF-7/R were incubated with hypericin
(HYP, 0.1mM–0.2mM) for 4h, washed and experimental groups were illuminated for 2min with blue light while dark controls were not exposed to light.
Cells were allowed to recover for a further 24h and were subjected to the MTT assay. Absorbance at 570nm corresponds to viability and was expressed as
a percentage of absorbance by untreated cells (y axis). Po0.05 for: MGHU1/R light vs dark, 0.2mM HYP; MCF-7/S light vs dark, 0.2mM HYP; MCF-7/S light vs
dark, 0.1mM HYP.
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shypericin (0.2mM)þMTZ (0.1mgml
 1) combination, compared to
MTZ alone (Po0.05) (Figure 5A). Similarly, MCF-7/R cells showed
significantly increased killing (80.20%, Po0.001; 46.10%, Po0.001)
with the hypericin (0.1mM)þMTZ (0.1mgml
 1) combination, com-
pared to hypericin or MTZ alone, respectively. MCF-7/R cells also
exhibited significantly increased cell killing, 37.60% decrease in cell
viability (Po0.01) (Figure 5B), with the hypericin (0.2mM)þMTZ
(0.1mgml
 1) combination compared to MTZ alone.
Dark control plates were run concurrently to investigate the effect of
illumination on viability when cells were treated with both hypericin
and MTZ. Results are presented in a composite graph (Figure 6).
MGHU1/R cells which were exposed to combinations of hypericin and
MTZ (0.1mMþ0.1mgml
 1) and illuminated showed significantly
more killing than their dark counterparts (28.15%, Po0.05). Although
there were also differences between light and dark in the other two
drug combinations, they did not quite reach significance. Similar
results were found for MCF-7/R cells (not shown).
Intracellular imaging of mitoxantrone and hypericin
Cells were incubated with drugs either alone or in combination
for the desired time and illuminated. Cells were left to recover
for different time points (from 1 to 24h) and typical images are
presented here. Throughout all imaging experiments hypericin was
localised only to the cytoplasm, whereas MTZ was also found in
the nucleus of sensitive cells or some illuminated MDR cells.
Where co-localisation was observed, the two agents often appeared
to co-exist as cytoplasmic vesicles. Early after illumination (1h),
all cell lines showed some cytoplasmic co-localisation of hypericin
and MTZ, as illustrated in Figure 7. At this time, both
drug-sensitive cell lines showed clear nuclear localisation of MTZ
as expected; illumination does not alter this pattern (Figure 7A).
At the same time MDR cell lines, which were not illuminated
(dark controls), showed no nuclear MTZ localisation, which is
typical of Pgp-overexpressing cells (Figure 7B). Interestingly, the
pattern of green fluorescence changed when resistant cells were
illuminated, with MTZ appearing to re-localise nearer to or within
the nucleus of some, but not all, cells. Hypericin localisation, which
was evident throughout the cytoplasm, did not appear to change
on illumination (Figure 7C). Parallel experiments where MDR
cells were treated with MTZ alone (and illuminated) did not show
any nuclear drug localisation (image not shown).
Figure 8 shows MCF-7 cell lines treated with both drugs, 4h after
illumination. Again there was clear nuclear MTZ localisation in
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Figure 5 Bladder cancer cells (A) MGHU1/S and MGHU1/R and breast cancer cells (B) MCF-7/S and MCF-7/R were incubated with hypericin alone
(HYP, 0.1 or 0.2mM) for 4h or with mitoxantrone (MTZ, 0.1 or 0.2mgml
 1) alone for 24h or with mitoxantrone (0.1 or 0.2mgml
 1) for 20h, followed by
4h incubation with mitoxantroneþhypericin (MTZ 0.1 or 0.2mgml
 1þHYP 0.1 mM or 0.2mM) and illuminated (2min) with blue light (on the combination
groups, the first number denotes the HYP concentration; the second number denotes the MTZ concentration). Cells were allowed to recover for a further
24h and were subjected to the MTT assay. Absorbance at 570nm corresponds to viability and was expressed as a percentage of absorbance by untreated
cells (y axis). *38.65%, 36.63% increased killing vs hypericin or MTZ alone, respectively, Po0.05; **34% increased killing vs MTZ alone, Po0.05; ***80.2,
46.1% increased killing vs hypericin or MTZ alone, respectively, Po0.001; ****37.6% increased killing vs MTZ alone, Po0.01.
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sMCF-7/S cells, as expected (Figure 8A). In the equivalent
illuminated MCF-7/R cells (Figure 8B) there was MTZ present in
the nucleus of some cells. There was clearer co-localisation of the
drugs compared to the sensitive cells. At 16h post-illumination,
the intranuclear MTZ fluorescence increased in some MDR cells,
with a striking example of MCF-7/R cells shown in Figure 8C. The
same patterns of drug and photosensitiser localisation over time
were seen for MGHU1 cell lines.
Images at 24h post-illumination showed more sparsely distri-
buted cultures with cells appearing stressed, especially sensitive
cells. Figure 8D is an image of MGHU1/S cells. Here there was lack
of significant localisation of MTZ to the nucleus. This is not
surprising, given that the majority of cells in these cultures would
have been successfully assaulted by treatment and had already died.
The remaining cells imaged here must have evaded MTZ-mediated
killing. The equivalent MGHU1/R cells (Figure 8E) show increased
hypericin retention compared to the parental cells and this is a
recurrent feature for resistant cells by 24h.
Co-incubation experiments with lysotracker green DND-26
showed some localisation between hypericin and lysotracker in
cytoplasmic vesicles (lysosomes, Figure 9). Illumination resulted in
some relocalisation of both lysotracker and hypericin (time lapse
observation 10min for lysotracker (signal bleached), 20min for
hypericin), without the signal disappearing dramatically or
dispersing.
Pgp expression on the addition of hypericin and
mitoxantrone
We used indirect immunofluorescence to investigate any changes
in Pgp expression upon the addition of the drugs, either alone or
in combination, over a 24h period. Overall, Pgp immunoflores-
cence showed no difference in protein expression, in either
illuminated specimens or in dark controls when imaged at a
variety of time intervals up to and including 24h post-illumina-
tion. Figure 10 shows the results of Pgp staining on the MGHU1/R
cell line treated with (1) hypericin, (2) MTZ, and (3) both agents.
Visually, the Pgp immunofluorescence is very similar, regardless
of drug exposure. Results for MCF-7/R were similar (not shown).
Furthermore, there was no apparent difference in Pgp expression
between dark or illuminated slides, at any time post-incubation
either (Figure 10D and E). Immunofluorescence of the sensitive
parental cell lines showed virtually no Pgp expression and
therefore no further drug incubation experiments were carried
out in these cell lines.
Pgp function
The integrity of Pgp function was investigated by measuring
Pgp-mediated Rhodamine123 efflux over 20min on confocal
microscopy, after the resistant cells were pre-incubated either with
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Figure 6 Viability of MDR bladder cancer cells under light and dark conditions. Cells were incubated with hypericin alone (HYP, 0.1 or 0.2mM) for 4h or
with mitoxantrone alone (MTZ, 0.1 or 0.2mgml
 1) for 24h or with mitoxantrone (0.1 or 0.2mgml
 1) for 20h, followed by 4h incubation with
mitoxantroneþhypericin (MTZ 0.1 or 0.2mgml
 1þHYP 0.1 mM or 0.2mM) and illuminated (2min) with blue light (on the combination groups, the first
number denotes the HYP concentration; the second number denotes the MTZ concentration). Parallel experiments were conducted in the dark. Cells were
allowed to recover for a further 24h and were subjected to the MTT assay. Absorbance at 570nm corresponds to viability and was expressed as a
percentage of absorbance by untreated cells (y axis). Statistical significance presented only for dark vs light combinations. *28.15% increased killing light vs
dark, Po0.05.
Figure 7 (A) MGHU1/S cells (low magnification), (B) and (C) MGHU1/R cells treated with 2mgml
 1 MTZ for 20h followed by 4h of incubation with
2mgml
 1 MTZþ2mM HYP. Specimens (A) and (C) were illuminated for 2min, specimen (B) is a dark control. Images were taken at 1h post-illumination.
The white arrows indicate nuclear MTZ in the MGHU1/S cell line. The red arrows show the nuclei of MGHU1/R cells (dark control) with no nuclear MTZ
localisation. The blue arrows show nuclear MTZ in some MGHU1/R cells (illuminated). (MTZ¼green; HYP¼red; co-localisation¼yellow).
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shypericin or increasing concentrations of verapamil, the classical
Pgp inhibitor. Hypericin pre-incubated cells lost 74% of fluorescent
Rhodamine123 signal after 20min of efflux compared to initial
amounts taken up (Table 1). This was similar to control untreated
cells, which lost 72.4%. In contrast, verapamil pre-incubated cells
lost fluorescence in a dose-related manner: the cells which received
the smallest verapamil concentration (0.1mM) lost 35.4% of signal,
for 1.0 mM verapamil the decrease was 20%, while for 10mM
verapamil the decrease was 13.5%. For the latter group, the range
( 14.8 to 25.9) indicates that during general efflux some cells were
taking up and retaining Rhodamine123, which was present in their
immediate environment, presumably effluxed by neighbouring cells.
Per cent decrease values for all verapamil doses were significantly
different from controls (Po0.01, Mann–Whitney).
DISCUSSION
Hypericin-induced photodynamic therapy
The first aim of this study was to determine the doses and duration
of illumination at which hypericin (PDT) resulted in minimal or no
killing for both resistant cell lines. Previous PDT studies on the
effect of hypericin on cultured fibroblasts or murine keratinocytes
Figure 8 Cells were treated with 2mgml
 1 MTZ for 20h followed by 4h of incubation with 2mgml
 1 MTZþ2mM HYP. Specimens were then
illuminated for 2min. Images were taken post-illumination at 4h for (A) MCF-7/S and (B) MCF-7/R; at 16h for (C) MCF-7/R; at 24h for (D) MGHU1/S and
(E) MGHU1/R. The white arrow (A) shows nuclear MTZ in an MCF-7/S cell. The blue arrows show nuclear localisation in MCF-7/R cells at 4h (B) and 16h
(C) post-illumination. At 24h (D, E) MGHU1/R cells appear to have more red fluorescence than MGHU1/S cells. (MTZ¼green; HYP¼red; co-
localisation¼yellow).
Figure 9 MGHU1/R cells treated with HYP 2mM according to the described timeline. Lysotracker green DND-26 (50nM) was added for half an hour
(end of incubation) (dark experiment). (A) hypericin signal, (B) lysotracker green DND-26, (C) overlay, showing co-localisation. White arrows point out
examples of areas of co-localisation. (hypericin¼red, Lysotracker green DND-26¼green, co-localisation¼yellow).
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shave shown concentration- and light-dependent phototoxicity
starting at 1.25 or 5mM, depending on cell type. The main line of
investigation of the light dependency of hypericin-induced PDT on
murine keratinocytes had centred on varying doses (joules) of
light (0.1–10Jcm
 2)( Y uet al, 1996; Theodossiou et al, 2004). We
observed the effect of a concentration range of hypericin (0.1–
1.0mM) over light exposure of 1, 2, or 5min. Generally, the paternal
drug-sensitive cell lines were more resistant to hypericin than their
MDR counterparts. A concentration- and light duration-dependent
cell killing of the MGHU1 cell lines was observed, with longer
exposure and higher concentrations resulting in higher toxicity, in
line with previous work in the field (Adreoni et al, 1994; Yu et al,
1996; Kamuhabwa et al, 2004; Theodossiou et al, 2004). Hypericin
at 0.2mM was the lowest concentration at our chosen duration of
illumination (2min), which resulted in significant cytotoxicity in
MGHU1/R cells, but this dose did not affect MGHU1/S growth.
The MCF-7 cell lines, exhibited a more complex response,
succumbing to phototoxic effects at higher hypericin doses (from
0.4mM for sensitive cells and from 0.2mM for resistant cells, 2min
illumination), but exhibiting apparent proliferation at lower doses.
Previous reports show that, in response to physical or chemical
stress, cells can activate signalling pathways, including the
mitogen-activated protein kinase (MAPK) and phosphotidylinositol-
3-kinase pathways (Oleinick and Evans, 1998; Moor, 2000;
Agostinis et al, 2002). Specifically in HeLa cells photosensitisation
with hypericin resulted in the rapid and sustained activation of
Jun N-terminal kinase-1 and MAPK (Assefa et al, 1999). These
molecules are capable of propagating a proliferation signal and this
may be the mechanism triggered in the MCF-7 cell lines in
response to low-dose hypericin photosensitisation. The differences
observed between the four cell lines appear to be independent of
the level of hypericin uptake as shown the level of fluorescence
emitted at 605nm. There was no significant difference in initial
hypericin uptake, with an average fluorescence intensity of 3.6–3.9
(arbitrary units) across all four cell lines.
Photochemical internalisation
The potentiating effects of PCI have previously been demonstrated
in vitro (Engesaeter et al, 2006) and in vivo (Selbo et al, 2001; Dietz
et al, 2005) and these results have been reviewed by Høgset
(Høgset et al, 2004). While most studies have been carried out
using amphiphilic photosensitisers (eg, TPPS2a) PCI has also been
demonstrated using a membrane localising sensitiser, ALA-
induced photoporphyrin IX. Selbo et al, 2001 administered the
photosensitiser aluminium disulphonated phthalocyanine by
intraperitoneal injection into athymic mice, followed (48h later)
by a single intratumoural injection of the protein toxin gelonin.
The findings indicated that the photosensitiser could become
localised in endosomes, in vivo, within the tumour cells and that
upon illumination it could be relocalised to the cytoplasm.
Furthermore, the treatment regime demonstrated that PCI of
Table 1 Rhodamine Efflux from MGHU1/R Cells
Treatment RD efflux (% decrease), 20min median (range)
VER 0.1 35.4 (28.8–50.4)
VER 1.0 20.0 (16.7–35.2)
VER 10 13.6 ( 14.8–25.9)
HYP 0.1 74.0 (58.8–94.8)
Control 72.4 (58.9–81.5)
Experimental cultures were preincubated with verapamil (VER, 0.1, 1.0, or 10 mM,
24h) or hypericin (HYP, 0.1mM, 4h, plus illumination). Cells were loaded with
Rhodamine123 (30min) and efflux semi-quantitated by confocal imaging, using 30s
slices, 20min. Per cent decrease refers to signal detected after 20min efflux
compared to signal at the beginning of efflux. Between 5 and 8 cells per coverslip
were calculated and results presented as medians (range). Rhodamine123 was
excited at 488nm and emission spectra detected at 510–550nm. Per cent decrease
values for all verapamil doses were significantly different from controls (Po0.01,
Mann–Whitney).
Figure 10 MGHU1/R cells treated with (A, D, E)2 mM HYP, (B)2 mgml
 1 MTZ and (C)2 mgml
 1 MTZþ2mM HYP, according to the described
timeline. Cells (A, B, C) were illuminated for 2min and the experiment was terminated 4h post-illumination. To determine the effect of light, cells were
either illuminated for 2min (E) or were kept as dark controls (D) and the experiment terminated at 24h. P-glycoprotein, detected by indirect
immunofluorescence (white), is situated mostly in the cellular membrane.
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sgelonin significantly potentiated its inhibition of tumour growth:
67% of mice administered PCI treatment became completely
tumour free, compared to 10% of those treated with PDT alone,
and none of those treated with gelonin alone.
In this study, illumination of MDR cancer cells which had been
pre-incubated with a combination of the photosensitiser hypericin
and the chemotherapeutic MTZ resulted in increased killing
compared to unilluminated dark controls. The effect was
pronounced at low concentrations of the two agents, 0.1mM
hypericin and 0.1mgml
 1 MTZ, using a 2min illumination period.
These particular concentrations of hypericin and MTZ were not
significantly cytotoxic when cells were exposed to each agent alone
(with or without light); on the contrary hypericin, when
photoactivated, appeared to stimulate MCF-7/R proliferation.
Furthermore, under light conditions (Figure 5A and B), there
was a 38.65% increase in killing of MGHU1/R cells when the drugs
were combined and illuminated compared to cells that received
PDT alone (ie, hypericin plus illumination) and a 36.63% increase
compared to MTZ alone. A similar pattern was observed in
MCF-7/R cells. These findings are consistent with PCI. Consequently,
by potentiating the cytotoxicity of MTZ, hypericin plus illumina-
tion appear to circumvent the MDR phenotype; since hypericin by
itself at the doses used does not affect cellular viability, the
combined effect is probably due to synergism. Furthermore,
hypericin potentiated the killing activity of MTZ on the sensitive
cell lines but this was minimal and not significant. Similarly, Canti
et al (1998) demonstrated that when antiblastic drugs, ADR and
cisplatinum (CDDP) were combined with the photosensitiser
aluminium disulphonated phthalocyanine it resulted in a sig-
nificant additive effect on the killing of murine leukaemia and
lymphoma lines, compared to ADR or CDDP alone.
Confocal imaging experiments explored the intracellular localisa-
tion of the two agents. The findings indicate that hypericin and
MTZ colocalised in cytoplasmic vesicles of both sensitive and MDR
cells both prior and following illumination. MTZ was present in the
nucleus of sensitive cells, as expected, at all experimental end-times
apart from those cells that survived the cytotoxic insult at 24h. MDR
cells when not illuminated excluded MTZ from the nucleus (in the
presence or absence of hypericin). However, when illuminated in the
presence of hypericin, some MTZ became nuclear (4 and 16h post-
illumination) and this was apparent in a proportion of cells.
Hypericin was cytoplasmic throughout and appeared to be retained
better by resistant cells compared to sensitive cells at 24h (compared
to the initial uptake of hypericin which appeared equivalent in all
cell lines, as determined by fluorescent plate reading). The
distribution of hypericin was similar for dark and illuminated cells
in our experiments. Furthermore, as reported in previous work by
colleagues, we showed hypericin partly co-localising with lysotracker
green DND-26, a marker known to bind to acidic membranes
(eg, lysosomal vesicles) (Theodossiou et al, 2004). This work is
supplemented by another study which highlighted that the presence
of serum during hypericin incubation favours endocytic uptake
(Siboni et al, 2002). We also showed co-localisation between
hypericin and MTZ, the latter may be taken up by endocytosis and
is retained inpart by lysosomes. Furthermore, following illumination,
part of the MTZ fluorescence appears to move towards and into the
nucleus of resistant cells. This suggests that co-localisation takes
place in endolysosomal compartments and that illumination
liberates MTZ, consequently facilitating the drug reaching its nuclear
target. Since MTZ is a weak base, then liberation from an acidic
vesicle, such as a lysosome (where MTZ is ‘ion-trapped’) would
increase the availability of this drug to intracellular targets (Mahoney
et al, 2003). The fact that the hypericin signal did not undergo major
changes upon illumination is not surprising since in an effort to
detect clear fluorescent signals the amounts used for our confocal
experiments were 10-fold greater than those used for the cell viability
experiments. Consequently, hypericin was detected throughout the
cell cytoplasm. Lou et al (2006) also showed nuclear localisation of
MTZ in MDR cells, however the underlying mechanisms differ in
that the photosensitiser (plus illumination) was administered before
chemotherapeutic insult. The latter probably resulted in the
destruction of endosomes and therefore their unavailability to
transport chemotherapeutic drug (Prasmickaite et al, 2002).
Whether increased killing effects were the result of changes in
Pgp efflux pump expression or function due to the addition of
hypericin was also investigated. The addition of either agent by
itself or in combination (þ/  illumination) resulted in no
changes in Pgp expression by MDR cell lines, as shown by
immunofluorescent staining. Efflux of Rhodamine123 via Pgp
pumps was detected by confocal microscopy. The method we used
was based on the seminal work by Wang et al (2000) where the
authors presented a flow cytometric method for investigating
inhibition of Pgp efflux. In our work, cells which were pre-
incubated with 0.1mM hypericin (plus illumination) did not
interfere with Rhodamine123 efflux, unlike cells pre-incubated
with verapamil (0.1 to 10mM). Doses for both agents were those
that resulted in increased killing in ‘drug-combination’ experi-
ments, therefore the amounts of both agents were pharmacologi-
cally active in our model system. The concentrations of agents
used are of prime consideration since previous reports have
presented superficially conflicting results on the action of St John’s
Wort constituents (hyperforin and hypericin) on Pgp expression
and function. St John’s Wort may alter the expression of various
membrane pumps and result in decreased bioavailability of a
variety of drugs. Hypericin at a concentration of 10mM induced
mRNA expression of the Pgp gene MRD1 in the human colorectal
carcinoma line LS180 (Gutmann et al, 2006). In contrast, Tian et al
(2005) reported that only hyperforin and not hypericin (at 0.1mM,
24–48h treatment) caused a time-/dose-dependent induction of
Pgp protein by the same cell line. Furthermore, hypericin at the
same concentration did not interfere with either digoxin efflux or
Pgp-mediated transcellular transport of digoxin. However, Wang
and his colleagues (2004) demonstrated that hypericin inhibited
Pgp-mediated efflux at high concentrations (10mM).
The present study demonstrates that the cytotoxic efficacy of
MTZ, against MDR cancer cell lines is increased when in
combination with hypericin under illuminated (light) compared
to dark conditions. Our experiments indicate that the two drugs do
co-localise within the cytoplasm and that upon illumination some
MTZ is mobilised to the nucleus. These observations appear to be
independent of any effect on Pgp expression and/or function and
are not mirrored under dark conditions. Taken collectively the
findings of this study are consistent with PCI. PCI has the potential
to have a wide impact in clinical practice, including (1) reducing
the systemic side effects of anti-cancer cytotoxic agents, for two
reasons, first by reducing the dose of drug required for a given
killing effect and second by conferring an increased level of
treatment selectivity as the cytotoxic effect will be greatest in areas
that are illuminated and minimised systemically; (2) widening the
therapeutic index of anti-cancer agents giving clinicians and
patients a wider scope of drug dosing and effect; (3) reversing
MDR, thus overcoming the major limiting factor in conventional
anti-cancer chemotherapy regimens; and (4) providing a potential
delivery mechanism for gene therapy (Høgset et al, 2004;
Engesaeter et al, 2006). Thus this potentially versatile technique
may provide a driving force for improving the delivery mecha-
nisms in many drug-mediated treatment regimens.
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